Acadia Pharmaceuticals (ACAD) Gross Profit (2016 - 2026)

Acadia Pharmaceuticals' Gross Profit history runs 11 years deep, the most recent figure standing at $243.3 million for Q1 2026.

• In Q1 2026, Gross Profit rose 8.64% year-over-year to $243.3 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 9.25% YoY), while the FY2025 annual figure was $982.5 million, up 12.16% from the prior year.
• Gross Profit was $243.3 million for Q1 2026 at Acadia Pharmaceuticals, down from $257.8 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $257.8 million in Q4 2025 to a low of $112.5 million in Q1 2022.
• Historically, Gross Profit has averaged $193.7 million across 5 years, with a median of $213.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Gross Profit advanced 0.51% in 2022, then jumped 58.98% in 2023.
• A 5-year view of Gross Profit shows it stood at $134.1 million in 2022, then jumped by 58.98% to $213.2 million in 2023, then gained by 11.56% to $237.8 million in 2024, then grew by 8.4% to $257.8 million in 2025, then fell by 5.62% to $243.3 million in 2026.
• The last three Gross Profit figures came in at $243.3 million (Q1 2026), $257.8 million (Q4 2025), and $257.0 million (Q3 2025), per Business Quant data.